Antibody drug conjugates (ADCs) are new classes of biological drugs formed by conjugation technology combining toxin with monoclonal antibody (mAb) through a linker, which combines the targeting ability of antibody to tumor cells and the potent killing ability of toxin to achieve the advantage complementary synergistic therapy, and in recent years have come into an outbreak. With 20 years of antibody drug discovery experience, ProBio provides a one-stop ADC discovery service to customers, accelerating their research speed from target to ADC preclinical candidate molecules and preempting the research track.
-
- High-throughput internalization assay screening with antibodies supernatant
- Conduct pharmacology study in advance to evaluate efficacy and safety
Balance functionality and safety
- 20+ discovery project experiences in ADC targets, including HER2, EGFR, and TROP2
- 60+ ADC naked antibody discovery project experience
- 100+ ADC bioassay project experience
Excellent track record
-
- Diverse antibody discovery technical campaigns: Hybridoma, phage display, single B cell screening, fully human antibody discovery
- 190+ ready-to-use payload-linker conjugates
- 7 types of ADC bioassay methods:
Live-cell imaging-based Internalization, Toxin-conjugated mAb based cytotoxicity assay, bystander effect study - One-stop service: pharmacodynamics, pharmacokinetics, toxicology
One-stop ADC discovery solution
By Jan. 2024
Considerations in ADC Discovery
-
Payload-linker
Choose suitable payloadChoose suitable linkerChoose suitable conjugation method -
-
Functionality, safety and developability
In vitro bioassayIn vivo pharmacologyDevelopability
One-stop ADC Discovery Solution
ProBio provides a one-stop ADC discovery solution from target to preclinical candidates (PCC) ordered by high-throughput screening of naked antibodies, identifying functional antibody leads in the early stage, and conducting pharmacology study before antibody optimization.
Service Highlights
- Diverse antibody discovery technical campaigns:
Hybridoma, phage display, single B cell screening, fully human antibody discovery etc.
Multiple technical routes in parallel to improve project success - Multiple molecular types:
Monoclonal antibody, bispecific monoclonal antibody, single domain antibody, antibody fragment
- High-throughput antibody screening strategy:
ProBio conducts high-throughput internalization screening in the supernatant screening stage to identify antibody leads with desirable internalization capability in the early discovery stage.
- One stop antibody optimization solution:
ProBio offers a comprehensive solution of ADC antibody optimization service based on functionality and developability, which includes antibody humanization, antibody affinity tuning, Fc engineering(ADCC,CDC, ADCP enhancement, Fc silence, half-life extension).
- Types of toxins available from ProBio (partial):
Payload categories Products Maytansinoid DM1, DM2, DM3, DM4 Auristatins MMAE, MMAD,MMAF Eribulin derivatives Eribulin Mesylate Tubulysins Tubulysin D, Tubulysin M PBD Dimer SG3199 Doxorubicin PNU-159682 Camptothecin Exatecan Mesylate Amanitin derivatives α-Amanitin TLRs derivatives Resiquimod STING derivatives Cyclic-di-GMP - ProBio offers a variety of ADC coupling modalities (Cysteine/Lysine based conjugation & site-specific conjugation) and evaluates conjugation quality based on the detection of DAR and ADC purity using a variety of methods including SDS-PAGE, HIC-HPLC, SEC-MS, RPLC-MS.
ProBio provides 7 different ADC bioassay methods for antibody internalization, cell cytotoxicity assays and bystander effect to meet the specific needs in ADC validation for our clients.
| Scope | Internalization assay | Cytotoxicity assay | Bystander effect | ||||
|---|---|---|---|---|---|---|---|
| Cell based assay | Live-cell imaging based Internalization |
Toxin-conjugated mAb based cytotoxicity assay | pH-Indicator based Internalization | Temperature shift based Internalization | Cell growth inhibition assay | Medium transfer assay | |
| General designation | IncuCyte | DT3C | FabFc-ZAP | pHrodo | Temperature Shift | Cytotoxicity assay | Bystander effect |
| Molecule | Naked Antibody | ADC or Toxin | ADC | ||||
| Analyzer | Live-Cell Analyzer | Microplate Reader | FACS | FACS | Microplate Reader/ Live-Cell Analyzer | Microplate Reader | |
| Feature | Real-time and kinetics analysis | High sensitivity High throughput Close to the cytotoxic MOA |
Specific | Cost-effective Susceptible to multiple factors |
High throughput | Simultaneous detection: Ag+ cell cytotoxicity and Ag- bystander effect | |
| Application | Most versatile Best choice |
Full range Cost-effective Alternative choice |
High material cost | Client favor | For clients with limited budget | Full range | Bystander effect Potential security |
80+ positive reference antibody dose-response curve (freely available)
Target cells 200+ tumor cell lines and 100+ overexpression cell lines
ProBio provides one-stop ADC in vivo pharmacology solution services including in vivo pharmacodynamic evaluation based on animals models, in vivo pharmacokinetics, preclinical toxicology studies, and biomarker assay, which are meet the compliance requirements for ADC declarations and assist you in faster, superior, and more provincial ADC development.
-
Extensive model resource
- Abundance of mouse strains
- 6 tumor bearing animal models
- 80+ Tumor cell models
- 200+ Tumor cell banks
- 24 Tumor indications
-
Pharmacokinetic experiments
- Method development and validation
- Pharmacokinetic experiments in cynomolgus monkeys and other primates
- Tissue distribution experiment
- Receptor mass experiments
-
Toxicological studies
- Toxicity with a single administration
- Dose exploration experiments
- Long-term toxicity testing
- Local toxicity
- Tissue cross-reactivity experiments
Watch Our On-demand Webinar
Accelerated ADC Development via Integrated Antibody Discovery Platform
